MCID: MLG069
MIFTS: 47

Malignant Hypertension

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Nephrological diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Malignant Hypertension

MalaCards integrated aliases for Malignant Hypertension:

Name: Malignant Hypertension 12 15 17 71
Hypertension, Malignant 43
Hypertension Malignant 54

Classifications:



External Ids:

Disease Ontology 12 DOID:10824
MeSH 43 D006974
NCIt 49 C3118
SNOMED-CT 67 70272006
UMLS 71 C0020540

Summaries for Malignant Hypertension

Disease Ontology : 12 A hypertension that is characterized by rapid onset of extremely high blood pressure.

MalaCards based summary : Malignant Hypertension, also known as hypertension, malignant, is related to malignant secondary hypertension and malignant renovascular hypertension. An important gene associated with Malignant Hypertension is REN (Renin), and among its related pathways/superpathways are cGMP-PKG signaling pathway and MicroRNAs in cardiomyocyte hypertrophy. The drugs Nifedipine and Hydrochlorothiazide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 A hypertensive emergency is high blood pressure with potentially life-threatening symptoms and signs... more...

Related Diseases for Malignant Hypertension

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 1
Hypertension, Essential 2 Hypertension, Essential 3
Hypertension, Essential 4 Hypertension, Essential 5
Hypertension, Essential 6 Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension
Hypertension Due to Gain-of-Function Mutations in the Mineralocorticoid Receptor

Diseases related to Malignant Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 369, show less)
# Related Disease Score Top Affiliating Genes
1 malignant secondary hypertension 32.8 REN AGTR1
2 malignant renovascular hypertension 32.7 REN EDN1 AGTR1
3 nephrosclerosis 31.0 AGTR1 ADAMTS13 ACE
4 hypertensive encephalopathy 30.6 REN AGTR1 ADAMTS13 ACE
5 hypertensive retinopathy 30.6 VWF REN AGTR1 ADAMTS13 ACE
6 uremia 30.5 VWF REN ACE
7 hypertension, diastolic 30.5 REN ACE
8 hemolytic uremic syndrome, atypical 1 30.5 VWF THBD CFHR2 CFH CD46 ADAMTS13
9 purpura 30.5 VWF THBD ADAMTS13 ACE
10 cardiac tamponade 30.4 REN NPPB ACE
11 microvascular complications of diabetes 3 30.2 REN AGTR1 ACE
12 cardiogenic shock 30.1 NPPB ADM
13 takayasu arteritis 30.1 VWF THBD EDN1
14 nonarteritic anterior ischemic optic neuropathy 30.1 EDN1 AGTR1 ACE
15 fibromuscular dysplasia 30.0 REN AGTR1 AGT ACE
16 hypertensive nephropathy 30.0 AGTR1 ACE
17 anuria 29.9 REN AGTR1 AGT ADAMTS13 ACE
18 acute kidney failure 29.9 REN NPPA CFH ADAMTS13
19 atrial standstill 1 29.9 NPPB NPPA ACE
20 urinary tract obstruction 29.9 REN AGTR1 ACE
21 thrombotic microangiopathy 29.8 VWF CFH CD46 ADAMTS13
22 retinal vascular disease 29.8 REN EDN1 ACE
23 conn's syndrome 29.8 REN NPPA CHGA AGTR1 ACE
24 glomerulonephritis 29.8 CFH CD46 AGTR1 ACE
25 polyhydramnios 29.8 REN NPPB EDN1
26 renal hypertension 29.7 REN NPPB EDN1 AGTR1 AGT ADM
27 renovascular hypertension 29.7 REN NPPB NPPA EDN1 AGTR1 ADM
28 disseminated intravascular coagulation 29.7 VWF THBD ADAMTS13
29 renal dysplasia 29.6 REN AGTR1 AGT ACE
30 pericardial effusion 29.6 REN NPPB NPPA ACE
31 eclampsia 29.6 THBD REN EDN1 AGT ACE
32 vesicoureteral reflux 1 29.6 REN AGTR1 AGT ACE
33 pheochromocytoma 29.6 REN NPPA EDN1 CHGA ADM ACE
34 cardiac arrest 29.6 THBD REN NPPB ACE
35 microvascular complications of diabetes 5 29.6 AGTR1 AGT ACE
36 catastrophic antiphospholipid syndrome 29.4 CFH ADAMTS13
37 portal hypertension 29.4 VWF EDN1 AGTR1 ADAMTS13 ACE
38 antiphospholipid syndrome 29.3 VWF THBD CFH ADAMTS13
39 polycystic kidney disease 29.3 REN EDN1 AGTR1 AGT ACE
40 renal artery disease 29.3 REN NPPA AGTR1 AGT ACE
41 vascular disease 29.2 VWF THBD REN NPPB EDN1 AGTR1
42 hemolytic anemia 29.1 VWF THBD CFH CD46 ADAMTS13
43 thrombotic thrombocytopenic purpura 29.1 VWF THBD CFH CD46 ADAMTS13
44 proliferative glomerulonephritis 29.1 EDN1 CFHR2 CFH
45 iga glomerulonephritis 29.0 REN CFHR2 CFH AGTR1 AGT ACE
46 pulmonary edema 29.0 REN NPPB NPPA EDN1 AGTR1 AGT
47 thrombocytopenia 28.8 VWF THBD EDN1 CFH CD46 ADAMTS13
48 arteries, anomalies of 28.8 VWF REN EDN1 CFHR2 AGTR1 ACE
49 pre-eclampsia 28.7 VWF THBD REN NPPA EDN1 AGTR1
50 diabetes mellitus 28.6 VWF THBD REN NPPB EDN1 AGTR1
51 membranoproliferative glomerulonephritis 28.6 CFHR2 CFH CD46
52 lipoprotein quantitative trait locus 28.5 VWF REN NPPB NPPA EDN1 AGTR1
53 congestive heart failure 28.5 REN NPPB NPPA EDN1 AGTR1 AGT
54 hemolytic-uremic syndrome 28.5 VWF THBD CFHR2 CFH CD46 ADAMTS13
55 diarrhea 28.3 THBD REN CFH CD46 ADAMTS13
56 end stage renal disease 28.3 TRPC6 THBD REN CFH CD46 AGTR1
57 cerebrovascular disease 28.1 VWF THBD REN NPPB NPPA AGTR1
58 kidney disease 28.0 TRPC6 THBD REN NPPB NPPA EDN1
59 systemic lupus erythematosus 27.9 VWF THBD CFHR2 CFH CD46 ADAMTS13
60 stroke, ischemic 27.9 VWF THBD REN NPPB NPPA AGTR1
61 hellp syndrome 27.7 VWF THBD EDN1 CFH CD46 ADM
62 chronic kidney disease 27.5 THBD REN NPPB NPPA EDN1 CFH
63 hypertension, essential 27.5 VWF TRPC6 TRPC3 THBD REN NPPB
64 malignant hypertensive renal disease 12.3
65 cardiac tuberculosis 10.5 NPPB ACE
66 renal artery obstruction 10.5 REN ACE
67 toxic myocarditis 10.5 NPPB ACE
68 orthostatic proteinuria 10.5 REN ACE
69 al amyloidosis 10.5 VWF ADAMTS13
70 chronic thromboembolic pulmonary hypertension 10.4 NPPB EDN1
71 colorectal cancer 5 10.4 VWF ADAMTS13
72 cholesterol embolism 10.4 REN ACE
73 vasculogenic impotence 10.4 NPPA ACE
74 unilateral absence of a pulmonary artery 10.4 VWF THBD
75 kidney papillary necrosis 10.4 REN ACE
76 iga nephropathy 1 10.4 AGTR1 ACE
77 left bundle branch hemiblock 10.4 REN NPPB ACE
78 severe nonproliferative diabetic retinopathy 10.4 REN ACE
79 first-degree atrioventricular block 10.4 NPPB ACE
80 pericardium disease 10.4 REN NPPB ACE
81 generalized atherosclerosis 10.4 VWF REN ACE
82 bombay phenotype 10.4 VWF ADAMTS13
83 pulmonary valve insufficiency 10.3 NPPB EDN1 ACE
84 extrinsic cardiomyopathy 10.3 REN NPPB ACE
85 meningococcal infection 10.3 AGTR1 AGT
86 chronic pulmonary heart disease 10.3 NPPB EDN1 ACE
87 potter's syndrome 10.3 REN AGT ACE
88 ureteral disease 10.3 REN AGTR1 ACE
89 chronic mountain sickness 10.3 NPPB EDN1
90 heart conduction disease 10.3 REN NPPB ACE
91 angina pectoris 10.3 NPPB EDN1 ACE
92 kidney hypertrophy 10.3 REN ACE
93 anterolateral myocardial infarction 10.3 NPPB NPPA ACE
94 posterior urethral valves 10.3 AGTR1 AGT ACE
95 hypoaldosteronism 10.3 REN NPPA ACE
96 acute mountain sickness 10.3 EDN1 AGTR1 ACE
97 raynaud disease 10.3 EDN1 AGTR1 ACE
98 myocardial stunning 10.3 EDN1 AGTR1 ACE
99 pure autonomic failure 10.3 REN NPPA ACE
100 sleep disorder 10.3 REN EDN1 ACE
101 encephalopathy 10.3
102 inappropriate adh syndrome 10.3 REN NPPB NPPA
103 thyroid angiosarcoma 10.3 VWF THBD
104 obstructive nephropathy 10.3 REN AGT ACE
105 acute kidney tubular necrosis 10.3 REN NPPA ACE
106 vein disease 10.3 VWF EDN1 ACE
107 hepatic vascular disease 10.3 VWF REN EDN1
108 limb ischemia 10.3 VWF EDN1 ACE
109 constrictive pericarditis 10.2 NPPB ACE
110 carotid body cancer 10.2 VWF CHGA
111 twin-to-twin transfusion syndrome 10.2 REN NPPA AGTR1
112 splenic sequestration 10.2 VWF ADAMTS13
113 inherited blood coagulation disease 10.2 VWF THBD ADAMTS13
114 idiopathic hypercalciuria 10.2 REN NPPA EDN1
115 pyelonephritis 10.2
116 raynaud phenomenon 10.2 VWF THBD EDN1
117 eisenmenger syndrome 10.2 VWF THBD EDN1
118 aortic valve insufficiency 10.2 VWF REN NPPB ACE
119 hypoplastic left heart syndrome 10.2 NPPB NPPA ACE
120 plantar fascial fibromatosis 10.2 AGTR1 AGT
121 tricuspid valve insufficiency 10.2 REN NPPB EDN1 ACE
122 tricuspid valve disease 10.2 REN NPPB EDN1 ACE
123 hemorrhagic disease 10.2 VWF THBD ADAMTS13
124 coronary stenosis 10.2 VWF NPPB ADAMTS13 ACE
125 patent ductus arteriosus 1 10.2 REN NPPB EDN1 ACE
126 adrenal gland pheochromocytoma 10.2
127 papilledema 10.2
128 adrenal gland disease 10.2 REN CHGA ACE
129 central sleep apnea 10.2 REN NPPB NPPA ACE
130 renal tubular dysgenesis 10.2 REN AGTR1 AGT ACE
131 mitral valve insufficiency 10.2 REN NPPB NPPA ACE
132 interstitial nephritis 10.1 REN AGTR1 AGT ACE
133 orthostatic intolerance 10.1 REN EDN1 AGTR1 ACE
134 collagen disease 10.1 VWF THBD NPPA
135 pulmonary artery disease 10.1 VWF THBD NPPB ACE
136 muscle hypertrophy 10.1 NPPA EDN1 AGT
137 intrinsic cardiomyopathy 10.1 REN NPPB NPPA ACE
138 carotid artery disease 10.1 VWF THBD REN ACE
139 adenoma 10.1
140 intracranial berry aneurysm 10.1 VWF REN EDN1 ADM
141 acquired von willebrand syndrome 10.1 VWF ADAMTS13
142 hepatorenal syndrome 10.1 REN NPPA EDN1 ACE
143 endocardium disease 10.1 VWF CFHR2 ACE
144 renal fibrosis 10.1 REN AGTR1 AGT
145 endocrine organ benign neoplasm 10.1 REN CHGA ADM
146 retinal detachment 10.1
147 systemic scleroderma 10.1
148 hypokalemia 10.1
149 atrial heart septal defect 10.1 NPPB NPPA EDN1 ACE
150 thrombosis 10.1
151 chronic pyelonephritis 10.1
152 vasculitis 10.1
153 migraine with or without aura 1 10.1 REN EDN1 ADM ACE
154 peripheral vascular disease 10.1 VWF THBD ACE
155 diabetic angiopathy 10.1 VWF THBD EDN1 ADM
156 yemenite deaf-blind hypopigmentation syndrome 10.0
157 thrombotic thrombocytopenic purpura, hereditary 10.0 CFH ADAMTS13
158 blood platelet disease 10.0 VWF CFHR2 ADAMTS13
159 paraganglioma 10.0
160 optic nerve disease 10.0
161 intracranial hypertension 10.0
162 polyarteritis nodosa 10.0
163 patent foramen ovale 10.0 VWF REN NPPB EDN1 ACE
164 acute poststreptococcal glomerulonephritis 10.0 NPPA EDN1 CFHR2
165 apnea, obstructive sleep 10.0 REN NPPB EDN1 AGT ACE
166 berylliosis 10.0 CFHR2 ACE
167 sleep apnea 10.0 REN NPPB EDN1 AGT ACE
168 coronary heart disease 1 10.0 VWF NPPB EDN1 AGTR1 ACE
169 mitral valve stenosis 10.0 VWF REN NPPB NPPA ACE
170 arteriosclerosis 10.0
171 macular retinal edema 10.0
172 heart valve disease 10.0 VWF REN NPPB NPPA ACE
173 idiopathic edema 9.9 NPPB NPPA EDN1 ADM ACE
174 peripheral artery disease 9.9 VWF THBD NPPB EDN1 ACE
175 aortic valve disease 1 9.9 VWF REN EDN1 AGTR1 ACE
176 autosomal dominant polycystic kidney disease 9.9 REN EDN1 AGTR1 AGT ACE
177 vaginal adenoma 9.9 CYP1A1 CHGA
178 pulmonary fibrosis, idiopathic 9.9 THBD EDN1 AGT ACE
179 acute pancreatitis 9.9
180 neuropathy 9.9
181 lupus erythematosus 9.9
182 otosclerosis 9.9 CD46 AGTR1 AGT ACE
183 vaginal benign neoplasm 9.9 CYP1A1 CHGA
184 horseshoe kidney 9.9 REN CHGA
185 diffuse scleroderma 9.9 EDN1 ACE
186 atherosclerosis susceptibility 9.9 VWF THBD EDN1 AGTR1 ACE
187 autoimmune disease of cardiovascular system 9.9 VWF THBD CFHR2 ADAMTS13
188 pulmonary embolism 9.9 VWF THBD NPPB NPPA ACE
189 liver cirrhosis 9.9 REN NPPA EDN1 ADM ADAMTS13
190 blood coagulation disease 9.9 VWF THBD CFHR2 ADAMTS13
191 sarcoidosis 1 9.9
192 scleroderma, familial progressive 9.9
193 deficiency anemia 9.9
194 nephrotic syndrome 9.9
195 focal segmental glomerulosclerosis 9.9
196 ischemia 9.9
197 brain edema 9.9
198 pancreatitis 9.9
199 adrenal adenoma 9.9
200 aldosterone-producing adenoma 9.9
201 headache 9.9
202 afibrinogenemia, congenital 9.8 VWF CFHR2 CD46
203 dense deposit disease 9.8 CFHR2 CFH
204 renal cell carcinoma, nonpapillary 9.8
205 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
206 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.8
207 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 9.8
208 microvascular complications of diabetes 4 9.8
209 microvascular complications of diabetes 6 9.8
210 microvascular complications of diabetes 7 9.8
211 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
212 renal hypoplasia 9.8
213 aortic dissection 9.8
214 malignant essential hypertension 9.8
215 hydrocephalus 9.8
216 hemopericardium 9.8
217 polyneuropathy 9.8
218 seminoma 9.8
219 rapidly progressive glomerulonephritis 9.8
220 aortitis 9.8
221 hypopituitarism 9.8
222 48,xyyy 9.8
223 aneurysm 9.8
224 seizure disorder 9.8
225 cocaine intoxication 9.8
226 tetralogy of fallot 9.8 REN NPPB NPPA EDN1 ADM ACE
227 diastolic heart failure 9.8 REN NPPB NPPA AGTR1 AGT ACE
228 hypertensive heart disease 9.8 REN NPPB NPPA AGTR1 AGT ACE
229 mitral valve disease 9.8 REN NPPB NPPA AGTR1 AGT ACE
230 complement factor h deficiency 9.7 CFH CD46
231 aortic valve disease 2 9.7 VWF REN NPPB NPPA AGT ACE
232 familial hypertension 9.7 REN NPPA CHGA AGTR1 AGT
233 systolic heart failure 9.7 VWF NPPB NPPA EDN1 AGT ACE
234 atypical hemolytic uremic syndrome with complement gene abnormality 9.6 THBD CFH CD46
235 genetic atypical hemolytic-uremic syndrome 9.6 THBD CFH CD46
236 enterocolitis 9.6 THBD CFH CD46
237 oligohydramnios 9.6 REN NPPB EDN1 AGTR1 AGT ADM
238 aortic aneurysm, familial abdominal, 1 9.6
239 abducens palsy 9.6
240 alcohol dependence 9.6
241 autoimmune disease 9.6
242 fibrosis of extraocular muscles, congenital, 1 9.6
243 intussusception 9.6
244 klippel-trenaunay-weber syndrome 9.6
245 porphyria, acute intermittent 9.6
246 schizophrenia 1 9.6
247 sturge-weber syndrome 9.6
248 renal hypodysplasia/aplasia 1 9.6
249 lipoid congenital adrenal hyperplasia 9.6
250 adrenal hyperplasia, congenital, due to steroid 11-beta-hydroxylase deficiency 9.6
251 hemangiopericytoma, malignant 9.6
252 myeloma, multiple 9.6
253 ocular motor apraxia 9.6
254 3-methylglutaconic aciduria, type iii 9.6
255 osteogenic sarcoma 9.6
256 gallbladder disease 1 9.6
257 ventricular fibrillation, paroxysmal familial, 1 9.6
258 body mass index quantitative trait locus 1 9.6
259 pulmonary disease, chronic obstructive 9.6
260 anxiety 9.6
261 severe cutaneous adverse reaction 9.6
262 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.6
263 intraocular pressure quantitative trait locus 9.6
264 lipoprotein glomerulopathy 9.6
265 membranous nephropathy 9.6
266 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.6
267 hyperlipoproteinemia, type iii 9.6
268 erythema multiforme 9.6
269 exanthem 9.6
270 seckel syndrome 9.6
271 extra-adrenal pheochromocytoma 9.6
272 cryptococcal meningitis 9.6
273 malignant pheochromocytoma 9.6
274 sensorineural hearing loss 9.6
275 neuroretinitis 9.6
276 monocular esotropia 9.6
277 silicosis 9.6
278 benign essential hypertension 9.6
279 amnestic disorder 9.6
280 cholesteatoma of middle ear 9.6
281 lipoid nephrosis 9.6
282 hydronephrosis 9.6
283 retinal vasculitis 9.6
284 iron deficiency anemia 9.6
285 cortical blindness 9.6
286 visual epilepsy 9.6
287 hemosiderosis 9.6
288 paranoid schizophrenia 9.6
289 pulsating exophthalmos 9.6
290 leukemia 9.6
291 posterior uveitis 9.6
292 severe pre-eclampsia 9.6
293 crescentic glomerulonephritis 9.6
294 uveitis 9.6
295 porphyria 9.6
296 facial paralysis 9.6
297 toxic shock syndrome 9.6
298 obstructive hydrocephalus 9.6
299 capillary leak syndrome 9.6
300 foster-kennedy syndrome 9.6
301 retinal vein occlusion 9.6
302 status epilepticus 9.6
303 urethral stricture 9.6
304 viral hepatitis 9.6
305 intermittent squint 9.6
306 leiomyosarcoma 9.6
307 intestinal perforation 9.6
308 constipation 9.6
309 pharyngitis 9.6
310 iron metabolism disease 9.6
311 central retinal vein occlusion 9.6
312 chondroma 9.6
313 cryoglobulinemia 9.6
314 kidney cortex necrosis 9.6
315 mixed connective tissue disease 9.6
316 retinitis 9.6
317 aortic aneurysm 9.6
318 pseudohermaphroditism 9.6
319 pulmonary fibrosis 9.6
320 adrenal carcinoma 9.6
321 hyperglycemia 9.6
322 hypertrichosis 9.6
323 pyoderma 9.6
324 rhinitis 9.6
325 poliomyelitis 9.6
326 paraplegia 9.6
327 fibromyalgia 9.6
328 connective tissue disease 9.6
329 cocaine abuse 9.6
330 polycythemia 9.6
331 malignant hyperthermia 9.6
332 amyloidosis 9.6
333 ocular hypertension 9.6
334 scotoma 9.6
335 exophthalmos 9.6
336 iridocyclitis 9.6
337 diabetes insipidus 9.6
338 meningitis 9.6
339 renal tuberculosis 9.6
340 esotropia 9.6
341 encephalocele 9.6
342 leukoplakia 9.6
343 phacomatosis pigmentovascularis 9.6
344 sudden sensorineural hearing loss 9.6
345 weber syndrome 9.6
346 cerebral aneurysms 9.6
347 dysphagia 9.6
348 pituitary tumors 9.6
349 spinal cord infarction 9.6
350 periodic paralysis 9.6
351 erythema multiforme major 9.6
352 rare vascular disease 9.6
353 acute liver failure 9.6
354 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.6
355 atrial fibrillation 9.5 VWF REN NPPB NPPA AGTR1 AGT
356 respiratory failure 9.5 THBD REN NPPB NPPA EDN1 ADM
357 diabetes mellitus, type i 9.5 REN NPPA CFHR2 AGTR1 AGT ACE
358 c3 glomerulopathy 9.5 CFHR2 CFH CD46
359 degeneration of macula and posterior pole 9.4 CFHR2 CFH CD46
360 hypertrophic cardiomyopathy 9.3 VWF REN NPPB NPPA EDN1 AGTR1
361 complement deficiency 9.3 CFHR2 CFH CD46 ADAMTS13
362 diabetes mellitus, noninsulin-dependent 9.3 VWF THBD REN EDN1 AGTR1 AGT
363 heart disease 9.2 VWF REN NPPB NPPA EDN1 AGTR1
364 dilated cardiomyopathy 9.1 VWF REN NPPB NPPA EDN1 AGTR1
365 malaria 9.1 VWF THBD EDN1 CFH AGTR1 ADAMTS13
366 acute myocardial infarction 9.0 VWF THBD REN NPPB NPPA EDN1
367 cardiovascular system disease 8.9 VWF THBD REN NPPB NPPA EDN1
368 pulmonary hypertension 8.8 VWF TRPC6 THBD REN NPPB NPPA
369 myocardial infarction 8.1 VWF THBD REN NPPB NPPA EDN1

Graphical network of the top 20 diseases related to Malignant Hypertension:



Diseases related to Malignant Hypertension

Symptoms & Phenotypes for Malignant Hypertension

MGI Mouse Phenotypes related to Malignant Hypertension:

45 (showing 8, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 ACE ADM AGT AGTR1 CD46 CFH
2 homeostasis/metabolism MP:0005376 10.18 ACE ADAMTS13 ADM AGT AGTR1 CFH
3 hematopoietic system MP:0005397 10.14 ACE ADAMTS13 ADM AGTR1 CFH CYP1A1
4 mortality/aging MP:0010768 10.07 ACE ADAMTS13 ADM AGT AGTR1 CFH
5 immune system MP:0005387 10.06 ACE ADAMTS13 ADM AGT AGTR1 CFH
6 muscle MP:0005369 9.76 ADM AGT CFH CHGA EDN1 NPPA
7 nervous system MP:0003631 9.7 AGT AGTR1 CD46 CFH CHGA EDN1
8 renal/urinary system MP:0005367 9.32 ACE ADM AGT AGTR1 CFH CHGA

Drugs & Therapeutics for Malignant Hypertension

Drugs for Malignant Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 75, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifedipine Approved Phase 4 21829-25-4 4485
2
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
3
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
4
Atenolol Approved Phase 4 29122-68-7 2249
5
Losartan Approved Phase 4 114798-26-4 3961
6
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
7
Amlodipine Approved Phase 4 88150-42-9 2162
8
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
9
Adalimumab Approved Phase 4 331731-18-1 16219006
10
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
11
leucovorin Approved Phase 4 58-05-9 6006 143
12
Tofacitinib Approved, Investigational Phase 4 477600-75-2
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14 Hormones Phase 4
15 Tocolytic Agents Phase 4
16 Adrenergic beta-Antagonists Phase 4
17 Sodium Chloride Symporter Inhibitors Phase 4
18 Neurotransmitter Agents Phase 4
19 Adrenergic beta-1 Receptor Antagonists Phase 4
20 Angiotensin II Type 1 Receptor Blockers Phase 4
21 Adrenergic Agents Phase 4
22 Angiotensin Receptor Antagonists Phase 4
23 Angiotensinogen Phase 4
24 Adrenergic Antagonists Phase 4
25 Anti-Arrhythmia Agents Phase 4
26 Giapreza Phase 4
27 Sympatholytics Phase 4
28 diuretics Phase 4
29 Antihypertensive Agents Phase 4
30 Angiotensin-Converting Enzyme Inhibitors Phase 4
31
protease inhibitors Phase 4
32 Vasodilator Agents Phase 4
33 HIV Protease Inhibitors Phase 4
34 Calcium, Dietary Phase 4
35 calcium channel blockers Phase 4
36 Cardiotonic Agents Phase 4
37 Protective Agents Phase 4
38 Antimetabolites Phase 4
39 Antibodies Phase 4
40 Immunoglobulins, Intravenous Phase 4
41 Immunologic Factors Phase 4
42 Anti-Inflammatory Agents Phase 4
43 Antirheumatic Agents Phase 4
44 Immunoglobulins Phase 4
45 Protein Kinase Inhibitors Phase 4
46 Vitamin B Complex Phase 4
47 Folic Acid Antagonists Phase 4
48 Immunosuppressive Agents Phase 4
49 Dermatologic Agents Phase 4
50 Folate Phase 4
51 Vitamin B9 Phase 4
52
Calcium Nutraceutical Phase 4 7440-70-2 271
53
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
54
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
55
Atorvastatin Approved Phase 3 134523-00-5 60823
56 Nigella Phase 3
57 Hypoglycemic Agents Phase 3
58
Diazoxide Approved Phase 2 364-98-7 3019
59
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 441203 84093
60
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
61
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
62
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
63
Choline Approved, Nutraceutical Phase 2 62-49-7 305
64 Gastrointestinal Agents Phase 2
65 Hypolipidemic Agents Phase 2
66 Lipid Regulating Agents Phase 2
67 Etoposide phosphate Phase 1, Phase 2
68 Albumin-Bound Paclitaxel Phase 1, Phase 2
69 Angiogenesis Inhibitors Phase 1
70 Antineoplastic Agents, Immunological Phase 1
71
Bevacizumab Approved, Investigational 216974-75-3
72
Testosterone Approved, Experimental, Investigational 58-22-0, 481-30-1 10204 6013
73 Cola
74 Hormone Antagonists
75 Androgens

Interventional clinical trials:

(showing 24, show less)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
2 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
3 Blood Pressure Reduction by Fixed-dose Compared to Free Dose Combination Therapy of ACE Inhibitor and Calcium Antagonist in Hypertensive Patients Completed NCT02995954 Phase 4 Perindopril/Amlodipine
4 Effects of Angiotensin Converting Enzyme Inhibitors on Peritoneal Protein Loss and Solute Transport in Peritoneal Dialysis Patients Completed NCT01575652 Phase 4
5 A Pilot Study in the Treatment of Severe Patients With Takayasu Arteritis With Tocilizumab and Adalimumab, Based on ECTA Cohort Recruiting NCT04300686 Phase 4
6 Randomized Open-label Study in Mild and Moderate Patients With Takayasu Arteritis Between Methotrexate and Tofacitinib Based on the ECTA Cohort. Recruiting NCT04299971 Phase 4 Methotrexate Tablets;Tofacitinib tablet
7 Effect of Nigella Sativa Seed Extract on the Blood Pressure of Elderly With Hypertension Unknown status NCT01393054 Phase 3 Nigella sativa
8 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
9 The Benefit of STent Placement and Blood Pressure and Lipid-Lowering for the Prevention of Progression of Renal Dysfunction Caused by Atherosclerotic Ostial Stenosis of the Renal Artery (STAR) Completed NCT00150943 Phase 3
10 A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Diazoxide Choline in Non-Diabetic Hypertriglyceridemic Subjects Completed NCT00696475 Phase 2 Diazoxide choline;Diazoxide choline;Diazoxide choline;Placebo
11 Phase I / II Clinical Study on the Safety and Preliminary Efficacy of Anlotinib Hydrochloride Combined With Platinum-containing Simultaneous Radiotherapy in the Treatment of Locally Advanced Non-small Cell Lung Cancer Recruiting NCT04182698 Phase 1, Phase 2 Simultaneous chemoradiotherapy for An Luo
12 Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial Unknown status NCT02672995 Phase 1 bevacizumab
13 Effect of Structured Education to Decrease Blood Pressure for Hypertension in Elderly : a Randomized Controlled Trial Unknown status NCT01834365
14 Transcatheter Renal Denervation in Patients With Systolic Heart Failure Due to Chagas' Disease - a Safety and Efficacy Study. Unknown status NCT02099903
15 Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy. Unknown status NCT01870310
16 Single Incision Laparoscopy Completed NCT00616616
17 Telemedical Versus Conventional Emergency Care of Hypertensive Emergencies and Urgencies Completed NCT02924805
18 Assessment of Renal and Cervical Artery DysplasIA Completed NCT02884141
19 Correlates of Nonadherence to Hypertension Treatment in an Inner-City Minority Population Completed NCT00005240
20 Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma Completed NCT01810744
21 Continue or Stop Applying Wet Cupping (Al-Hijamah) in Migraine Headache: A Randomized Control Trial Completed NCT03479060
22 A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort Recruiting NCT03755726
23 Serum Androgen Levels as a Marker for the Severity of Preeclampsia Active, not recruiting NCT03744988
24 Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834

Search NIH Clinical Center for Malignant Hypertension

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Captopril
Diazoxide
Enalapril
Enalapril Maleate
Enalaprilat
Fenoldopam
Fenoldopam Mesylate
Hydralazine
Hydralazine Hydrochloride
Labetalol
Labetalol hydrochloride
Mecamylamine
Mecamylamine hydrochloride
Minoxidil
nebivolol
Phenoxybenzamine
Phenoxybenzamine Hydrochloride
Phentolamine
Phentolamine Mesylate
Sodium Nitroprusside
trimethaphan camsylate

Cochrane evidence based reviews: hypertension, malignant

Genetic Tests for Malignant Hypertension

Anatomical Context for Malignant Hypertension

MalaCards organs/tissues related to Malignant Hypertension:

40
Kidney, Heart, Brain, Eye, Testes, Liver, Endothelial

Publications for Malignant Hypertension

Articles related to Malignant Hypertension:

(showing 1968, show less)
# Title Authors PMID Year
1
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. 61 54
18332284 2008
2
The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. 54 61
17679041 2007
3
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. 61 54
17485026 2007
4
Angiotensin-converting enzyme i/d polymorphism in patients with malignant hypertension. 54 61
15655381 2005
5
The role of the renin-angiotensin system in malignant vascular injury affecting the systemic and cerebral circulations. 54 61
14769441 2004
6
Recovery from renal failure in malignant hypertension associated with primary aldosteronism: effect of an ACE inhibitor. 61 54
11861963 2002
7
Angiotensin-converting enzyme gene I/D polymorphism in malignant hypertension. 54 61
10855732 2000
8
Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. 61 54
10221353 1999
9
The importance of the renin-angiotensin system in cardiovascular disease. 54 61
9655650 1998
10
The Tsukuba hypertensive mouse (transgenic mouse carrying human genes for both renin and angiotensinogen) as a model of human malignant hypertension: development of lesions and morphometric analysis. 61 54
9504863 1998
11
Nephrosclerosis and hypertension. 54 61
9356598 1997
12
Malignant hypertension in a patient with primary aldosteronism with elevated active renin concentration. 54 61
9372330 1997
13
Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension. 54 61
10968202 1996
14
Hyperrenin-hyperaldosterone-dependent malignant hypertension in polyarteritis nodosa. 54 61
7903825 1993
15
Blood pressure, angiotensin-converting enzyme (ACE) inhibitors, and the kidney. 54 61
1580276 1992
16
Angiotensin converting enzyme inhibitors in cardiovascular and renal disease in Africans: a review. 54 61
1908620 1991
17
Renal disorders in rheumatologic diseases: the spectrum is changing (Part 1: connective tissue diseases). 61
32529559 2020
18
Rapidly progressive glomerulonephritis and acute kidney injury associated with cocaine use - Case report. 61
32573647 2020
19
Subendocardial stress in pre-eclampsia. 61
32501623 2020
20
A New Paradigm for Renal Thrombotic Microangiopathy. 61
32085935 2020
21
Efficacy of trazodone for treating paroxysmal sympathetic hyperactivity presenting after left temporal subcortical hemorrhage. 61
32494561 2020
22
Clinical value of multiorgan damage in hypertensive crises: A prospective follow-up study. 61
32271999 2020
23
Correlations Between Interleukin-11 Expression and Hypertensive Kidney Injury in a Rat Model of Renovascular Hypertension. 61
31840157 2020
24
Advancements in medical and surgical treatments of Takayasu arteritis-induced renal arteritis: a systematic review. 61
32187045 2020
25
Unraveling the Role of Interleukin-11 in Renal and Cardiac Fibrosis in Malignant Hypertension. 61
32030403 2020
26
Entrapped renal artery in the left crux of diaphragm: a rare cause of malignant hypertension. 61
32352070 2020
27
[The 476th case: skin rash, edema, thrombocytopenia and anemia]. 61
32146758 2020
28
Clinical Profile and Outcome of IgA Nephropathy from a Tertiary Care Hospital in North India. 61
32138477 2020
29
Aliskiren as an adjunct therapy for atypical hemolytic uremic syndrome. 61
32083614 2020
30
Pharmacological management of malignant hypertension. 61
32100590 2020
31
Recovery of Renal Function in a Kidney Transplant Patient After Receiving Hemodialysis for 4 Months. 61
30066627 2020
32
Malignant hypertension: does this still exist? 61
31636349 2020
33
Phaeochromocytoma of the urinary bladder presenting with malignant hypertension and hypertensive retinopathy. 61
31970077 2020
34
Myocardial Infarction as the Initial Presentation for Fibromuscular Dysplasia. 61
32462080 2020
35
Serotonin Syndrome Presenting as a Posterior Reversible Encephalopathy Syndrome. 61
32231545 2020
36
CONN SYNDROME PRESENTING AS CENTRAL RETINAL VEIN OCCLUSION. 61
28644176 2020
37
Complement Activation and Thrombotic Microangiopathies. 61
31694864 2019
38
[Malignant hypertension: A bright future]. 61
31471092 2019
39
Serous retinal detachment in preeclampsia and malignant hypertension. 61
31089238 2019
40
Comment on: "Serous retinal detachment in preeclampsia and malignant hypertension". 61
31278383 2019
41
Elevated Plasma Renin Activity Caused by Accelerated-malignant Hypertension in a Patient with Aldosterone-producing Adenoma Complicated with Renal Insufficiency. 61
31292373 2019
42
Demyelinating syndrome in systemic sclerosis and neuromyelitis optica. 61
31607267 2019
43
[Cerebral amyloid angiopathy revealed or hypertension-related cerebral small vessel diseases: A clinical challenge]. 61
31466725 2019
44
Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. 61
31420192 2019
45
Takayasu arteritis: differential diagnosis in a teenager with severe acute kidney injury - a case report. 61
30638252 2019
46
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. 61
31733722 2019
47
Hyperhomocysteinemia: a trigger for complement-mediated TMA? 61
31401947 2019
48
Atypical Presentation of Renal Leiomyosarcoma: A Case Report. 61
31632881 2019
49
Posterior reversible encephalopathy syndrome in stroke-prone spontaneously hypertensive rats on high-salt diet. 61
29350576 2019
50
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis. 61
30809002 2019
51
Patterns of renal disease: A 30-year renal biopsy study at Chris Hani Baragwanath Academic Hospital, Soweto, Johannesburg, South Africa. 61
31266574 2019
52
Systemic Sclerosis with Focus on Scleroderma Renal Crisis. 61
31209194 2019
53
Takayasu arteritis, malignant hypertension and severe left ventricular hypertrophy. 61
30861323 2019
54
Factors associated with adverse outcomes from cardiovascular events in the kidney transplant population: an analysis of national discharge data, hospital characteristics, and process measures. 61
31138156 2019
55
Hypertensive Choroidopathy Revealing Malignant Hypertension in a Young Patient. 61
30893276 2019
56
Fundoscopy and malignant hypertension. 61
30395318 2019
57
Etiology and Outcomes of Thrombotic Microangiopathies. 61
30862697 2019
58
The exaggerated salt-sensitive response in hypertensive transgenic rats (TGR mRen-2) fostered by a normotensive female. 61
30531845 2019
59
The conundrum of postpartum thrombotic Microangiopathy: case report and considerations for management. 61
30871486 2019
60
Malignant hypertension: not quite an obsolete diagnosis yet. 61
30640869 2019
61
Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort. 61
30160657 2019
62
Macular edema secondary to malignant Hypertension managed with Intravitreal Bevacizumab. 61
31523075 2019
63
Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. 61
30891033 2019
64
A Case of Rheumatoid Arthritis Presenting with Renal Thrombotic Microangiopathy Probably due to a Combination of Chronic Tacrolimus Arteriolopathy and Severe Hypertension. 61
30963011 2019
65
Conditions and Factors Associated With Spontaneous Coronary Artery Dissection (from a National Population-Based Cohort Study). 61
30477805 2019
66
Inherited risk plus prenatal insult caused malignant dysfunction in mesenteric arteries in adolescent SHR offspring. 61
31017969 2019
67
Optical coherence tomography angiography findings in malignant hypertensive retinopathy. 61
30652771 2019
68
Long-term benefit of renal denervation on blood pressure control in a patient with hemorrhagic stroke. 61
31489195 2019
69
Awakening the sleeping kidney in a dialysis-dependent patient with fibromuscular dysplasia: A case report and review of literature. 61
30510913 2018
70
Renal involvement in antiphospholipid syndrome. 61
29730854 2018
71
Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States. 61
29544033 2018
72
20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. 61
30054426 2018
73
Therapy of scleroderma renal crisis: State of the art. 61
30005860 2018
74
Multiple Sclerosis Drug Fingolimod Induces Thrombotic Microangiopathy in Deoxycorticosterone Acetate/Salt Hypertension. 61
30354753 2018
75
The case report of capillary leakage syndrome secondary to malignant hypertension. 61
30142799 2018
76
Malignant Hypertension in Association with Low Estrogen Dose Oral Contraceptives: Case Report and Review of Literature. 61
30237939 2018
77
Forced Diuresis and Expedient Blood Pressure Control in the Management of Quetiapine Induced Neuroleptic Malignant Syndrome: A Case Report. 61
30087734 2018
78
Balloon angioplasty of renal artery stenosis due to Takayasu arteritis in a 2-year-old child. 61
29784504 2018
79
An elderly man with gastric cancer, Saint's triad and Heyde's syndrome. 61
30540734 2018
80
Outcomes of acute kidney injury in a department of internal medicine in ABIDJAN (cote D'IVOIRE). 61
28444694 2018
81
Severe renal failure and thrombotic microangiopathy induced by malignant hypertension successfully treated with spironolactone. 61
29753419 2018
82
Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. 61
29582550 2018
83
Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. 61
29419916 2018
84
Takayasu arteritis with an initial presentation of chronic monoarthritis mimicking oligoarticular juvenile idiopathic arthritis. 61
30069294 2018
85
Valsartan Effective for Malignant Hypertension after Aortic Dissection with Renal Artery Involvement. 61
29489021 2018
86
Inflammatory optic disc edema due to Sarcoidosis mimicking malignant hypertension. 61
25351429 2018
87
Intraoperative cone beam computed tomography-guided endovascular recanalization of an interrupted aorta. 61
29463459 2018
88
Cure With Cryoablation of Arterial Hypertension Due to a Renin-Producing Tumor. 61
29522074 2018
89
Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy. 61
29148534 2018
90
Comparison of acute kidney injury of different etiology reveals in-common mechanisms of tissue damage. 61
29341864 2018
91
[Acute kidney injury and rhabdomyolysis after cocaine overdose: case report and literature review]. 61
29582960 2018
92
A case of malignant hypertension with thrombotic microangiopathy. 61
29512323 2018
93
Mortality in the elderly with acute kidney injury in an internal medicine department in Abidjan, Cote D'Ivoire. 61
29657212 2018
94
[Atypical hemolytic uremic syndrome. Report of two cases treated with Eculizumab]. 61
29999163 2018
95
Endovascular treatment of coarctation and related aneurysms. 61
24918193 2018
96
[Acute kidney injury related to acute vascular disorders]. 61
30801143 2018
97
Membranous nephropathy followed by anti-glomerular basement disease: A case report and review of clinical presentation and treatment. 61
30364512 2018
98
Paraganglioma of Urinary Bladder Managed by Laparoscopic Partial Cystectomy in Conjunction with Flexible Cystoscopy: A Case Report. 61
29468198 2018
99
Thrombomodulin and Endothelial Dysfunction: A Disease-Modifier Shared between Malignant Hypertension and Atypical Hemolytic Uremic Syndrome. 61
29940557 2018
100
Malignant Hypertension Causing a Pulmonary-Renal Syndrome. 61
30652035 2018
101
'Malignant' hypertension from hyperaldosteronism: a case report. 61
30123413 2018
102
Posterior reversible encephalopathy syndrome (PRES) in mesenteric leiomyosarcoma: A case report. 61
29980031 2018
103
Case Report: 52-Year-Old Male with Right Upper Quadrant Abdominal Pain. 61
31360915 2018
104
World's First 24/7 Mobile Stroke Unit: Initial 6-Month Experience at Mercy Health in Toledo, Ohio. 61
29867711 2018
105
The costs of repatriating an ill seafarer: a micro-costing approach. 61
29209881 2017
106
The Etiology of Arteriolar Injury in Malignant Hypertension. 61
29059304 2017
107
Response to: The Cause of the Arteriolar Injury in Malignant Hypertension. 61
28985311 2017
108
Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant Hypertension Registry. 61
28622157 2017
109
Endoscopic ultrasound-guided placement of plastic pigtail stents for the drainage of refractory malignant ascites. 61
29250586 2017
110
Orbital haematoma in malignant hypertension. 61
28173968 2017
111
Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury. 61
28716988 2017
112
Multimodal imaging of hypertensive chorioretinopathy by swept-source optical coherence tomography and optical coherence tomography angiography: Case report. 61
28953634 2017
113
Malignant Hypertension Complicated By Renal Thrombotic Micro Angiopathy: Role Of Adam 13 Mutational Analyses. 61
29076694 2017
114
Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity. 61
28975130 2017
115
Nationwide review of hormonally active adrenal tumors highlights high morbidity in pheochromocytoma. 61
28688648 2017
116
Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. 61
27848226 2017
117
Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. 61
28187980 2017
118
Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect? 61
28501299 2017
119
Malignant Hypertension Revisited-Does This Still Exist? 61
28200072 2017
120
Malignant hypertension as a rare cause of thrombotic microangiopathy. 61
28596204 2017
121
[Moyamoya disease associated with kidney angiodysplasia in a child]. 61
28341559 2017
122
Complex glomerular pathology of thrombotic microangiopathy and focal segmental glomerulosclerosis forms tumor-like mass in a renal transplant donor with severe renovascular hypertension. 61
28509120 2017
123
Rapid sealing of porcine renal blood vessels, ex vivo, using a high power, 1470-nm laser, and laparoscopic prototype. 61
28550708 2017
124
Anti-angiotensin II type 1 receptor autoantibodies (AT1R-AAs) in patients with systemic sclerosis: lack of association with disease manifestations. 61
28004166 2017
125
SPONTANEOUS BILATERAL HEMORRHAGIC CHOROIDAL DETACHMENTS ASSOCIATED WITH MALIGNANT HYPERTENSION. 61
27177073 2017
126
[Optic disc changes by optical coherence tomography in optic disc edema in Lomé]. 61
28336281 2017
127
Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. 61
28356668 2017
128
Successful percutaneous CT-guided microwave ablation of adrenal gland for ectopic Cushing syndrome. 61
27919009 2017
129
Case report of a rarely seen long-segment middle aortic syndrome. 61
28424443 2017
130
Patterns of Care and Outcomes in Cardiovascular Disease After Kidney Transplantation in the United States. 61
28361110 2017
131
A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin. 61
28225482 2017
132
Emergency Department Use among Patients with CKD: A Population-Based Analysis. 61
28119410 2017
133
Takayasu arteritis presenting with malignant hypertension; a rare manifestation of a rare disease: a case report and review of the literature. 61
27216226 2017
134
Acute visual loss in a patient with spinal cord injury. 61
29423286 2017
135
Primitive Neuroectodermal Tumor and Wegener's Granulomatosis of the Kidney: A Curious Combination of Two Rare Entities. 61
28835865 2017
136
Response of Renal Podocytes to Excessive Hydrostatic Pressure: a Pathophysiologic Cascade in a Malignant Hypertension Model. 61
29224013 2017
137
Thrombotic microangiopathy due to malignant hypertension complicated with late-onset bleeding after renal biopsy. 61
28679995 2017
138
Current Status of Renal Artery Angioplasty and Stenting for Resistant Hypertension: A Case Series and Review of the Literature. 61
28782466 2017
139
THE SPECTRUM OF AMALRIC TRIANGULAR CHOROIDAL INFARCTION. 61
27780182 2017
140
Plasma heme-induced renal toxicity is related to a capillary rarefaction. 61
28071761 2017
141
First reported case of khat cardiomyopathy and malignant hypertension in Australia. 61
27981767 2016
142
Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. 61
26467267 2016
143
Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats. 61
27916218 2016
144
Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. 61
27876016 2016
145
Idiopathic midaortic syndrome with malignant hypertension in 3-year-old boy. 61
28018454 2016
146
Brain Natriuretic Peptide Counteracting the Renin-angiotensin-aldosterone System in Accelerated Malignant Hypertension. 61
27865304 2016
147
[Beware, polyarteritis nodosa still exists in nephrology!] 61
27686032 2016
148
Potentially Preventable Hospitalization among Patients with CKD and High Inpatient Use. 61
27821636 2016
149
Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma. 61
27849336 2016
150
Post-Partum Malignant Hypertension in a Patient with Preeclampsia and Abruptio Placenta. 61
29939706 2016
151
Booker T. Washington and the Secret of Hypertension in African Americans. 61
27776724 2016
152
Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. 61
27428043 2016
153
Posterior reversible encephalopathy syndrome in malignant hypertension secondary to focal segmental glomerulosclerosis. 61
27535734 2016
154
Incidence, aetiology and mortality secondary to hypertensive emergencies in a large-scale referral centre in Israel (1991-2010). 61
26674757 2016
155
From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. 61
26582411 2016
156
Elevated blood pressure is not associated with accelerated glomerular filtration rate decline in the general non-diabetic middle-aged population. 61
27188503 2016
157
A case report of malignant hypertension in a young woman. 61
27389397 2016
158
[Hypertensive crisis and sudden change of vision in young patients]. 61
26847495 2016
159
[Thrombotic microangiopathy : Relevant new aspects for intensive care physicians]. 61
27255224 2016
160
[Malignant hypertension and cardiac decompensation after overuse of nasal decongestant: A case report and literature review]. 61
26526778 2016
161
CD4(+)CD25(+) T Cells in primary malignant hypertension related kidney injury. 61
27278520 2016
162
[Clinical and etiological profile malignant hypertension in children in pediatric intensive care]. 61
27180561 2016
163
Clinicopathological features and risk factors analysis of IgA nephropathy associated with acute kidney injury. 61
27050722 2016
164
Renal Artery Stenosis - are there Patients who Benefit from Intervention? 61
27219892 2016
165
IMAGES IN CLINICAL MEDICINE. Reversible Loss of Vision in Malignant Hypertension. 61
27050208 2016
166
The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. 61
26778772 2016
167
Does Anticomplement Therapy Have a Role in the Management of Malignant Hypertension? 61
26359936 2016
168
A global amnesia associated with the specific variant of posterior reversible encephalopathy syndrome (PRES) that developed due to severe preeclampsia and malignant hypertension. 61
27099774 2016
169
Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. 61
26833491 2016
170
[Posterior Reversible Encephalopathy Syndrome Associated with Cancer Therapy]. 61
26965062 2016
171
An ectopic renin-secreting adrenal corticoadenoma in a child with malignant hypertension. 61
26997629 2016
172
The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients. 61
26675563 2016
173
Percutaneous Transluminal Angioplasty Improved Posterior Reversible Encephalopathy Syndrome due to Renovascular Hypertension. 61
26646732 2016
174
Diffuse Alveolar Hemorrhage Due to Malignant Arterial Hypertension - an Unusual Manifestation of a Common Disease. 61
30151450 2016
175
Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. 61
27766045 2016
176
Malignant hypertension-associated thrombotic microangiopathy following cocaine use. 61
26787585 2016
177
Malignant hypertension: new aspects of an old clinical entity. 61
26658350 2016
178
Malignant Hypertension with Thrombotic Microangiopathy. 61
27523008 2016
179
Renal artery bilateral arteriosclerosis cause of resistant hypertension in hemodialysed patients. 61
27516040 2016
180
Posterior Reversible Encephalopathy Syndrome with Extensive Deep White Matter Lesions Including the Temporal Pole. 61
27904123 2016
181
Impaired Neovascularization and Reduced Capillary Supply in the Malignant vs. Non-malignant Course of Experimental Renovascular Hypertension. 61
27625610 2016
182
Facial nerve palsy in a 3-year-old child with severe hypertension. 61
25983271 2015
183
Nephrosclerosis: update on a centenarian. 61
25488894 2015
184
[Malignant hypertension]. 61
26418709 2015
185
Bilateral exudative retinal detachment with choroidopathy in malignant hypertension. 61
27132968 2015
186
Candida-associated pseudo-aneurysm of the transplant renal artery presenting as malignant hypertension and managed successfully without nephrectomy. 61
26354578 2015
187
Renal Artery Stenosis: Optimal Therapy and Indications for Revascularization. 61
26238738 2015
188
A Case of Membranous Glomerulonephritis with Superimposed Anti-Neutrophil Cytoplasmic Antibody-Associated Rapidly Progressive Crescentic Glomerulonephritis. 61
26306306 2015
189
A case report of reninoma: radiological and pathological features of the tumour and characterization of tumour-derived juxtaglomerular cells in culture. 61
26132761 2015
190
Pheochromocytoma Diagnosis After an Abnormal Stress Test: Case Report and Review of the Literature. 61
26111142 2015
191
Scleroderma renal crisis as an initial presentation of systemic sclerosis: a case report and review of the literature. 61
25797912 2015
192
[Hypertensive emergencies and urgencies]. 61
26248707 2015
193
C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies. 61
25726938 2015
194
Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. 61
26137201 2015
195
Malignant Hypertension and Thrombotic Thrombocytopenic Purpura: False Friends. 61
26083445 2015
196
Scleroderma renal crisis. 61
25613774 2015
197
Current evidence regarding chimney graft occlusions in the endovascular treatment of pararenal aortic pathologies: a systematic review with pooled data analysis. 61
25878021 2015
198
Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States. 61
25801877 2015
199
Assessment of toxic elements in the samples of different cigarettes and their effect on the essential elemental status in the biological samples of Irish hypertensive consumers. 61
25273861 2015
200
Limitation of imaging in identifying iatrogenic aortic coarctation following thoracic endovascular aortic repair. 61
25637574 2015
201
Malignant hypertension: clinical manifestations of 7 cases. 61
25902134 2015
202
Severe visual loss caused by unrecognized malignant hypertension in a 15-year-old girl. 61
25868960 2015
203
Malignant hypertension in lgA nephropathy. 61
25761814 2015
204
[Hypertensive choroidopathy under malignant hypertension]. 61
25601708 2015
205
[Rare forms of hypertension : From pheochromocytoma to vasculitis]. 61
25700646 2015
206
Hypertension, end-stage renal disease and mesangiocapillary glomerulonephritis in methamphetamine users. 61
26294827 2015
207
Facial nerve palsy in the setting of malignant hypertension: a link not to be missed. 61
22696152 2015
208
Bilateral stellate neuroretinitis revealing a pheochromocytoma. 61
25995810 2015
209
Malignant hypertensive retinopathy as a presenting sign of an occult dead fetus. 61
26082609 2015
210
[Thrombotic thrombocytopenic purpura and tuberculosis. A rare association]. 61
26339877 2015
211
Characteristics of podocyte injury in malignant hypertensive nephropathy of rats (MSHRSP/Kpo strain). 61
26522148 2015
212
Catastrophic APS in the context of other thrombotic microangiopathies. 61
25604575 2015
213
Scleroderma renal crisis in tropical region: two senegalese cases. 61
26405482 2015
214
Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis. 61
25611832 2015
215
Basal transethmoidal encephalocele and malignant hypertension in a parturient with a seizure disorder. A case report. 61
25745752 2015
216
Tremendous result of bevacizumab in malignant hypertensive retinopathy. 61
25709280 2015
217
Pregnancy in women undergoing hemodialysis: case series in a Southeast Brazilian reference center. 61
25607123 2015
218
Renal artery stenosis precipitates hyponatremic hypertensive syndrome and posterior reversible leukoencephalopathy. 61
26000267 2015
219
Serum nitrate and nitrite levels in patients with hypertension and ischemic stroke depend on diet: a multicenter study. 61
25445235 2015
220
Malignant hypertension with thrombotic microangiopathy and persistent acute kidney injury (AKI). 61
25503954 2014
221
Cocaine and kidney injury: a kaleidoscope of pathology. 61
25859366 2014
222
The future of renal denervation in resistant hypertension. 61
25304105 2014
223
Renal fibromuscular dysplasia with malignant hypertension cured by balloon angioplasty with stenting. 61
24927042 2014
224
Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. 61
25224811 2014
225
Blood-retina-barrier disruption accompanying blood-brain-barrier dysfunction in posterior reversible encephalopathy syndrome. 61
25218416 2014
226
Use of a pulsatile perfusion pump for renal autotransplantation in a patient undergoing thoracoabdominal bypass for malignant hypertension secondary to Takayasu arteritis. 61
24698771 2014
227
Pseudopheochromocytoma induced by anxiolytic withdrawal. 61
25288254 2014
228
An 18-year-old female patient with malignant hypertension masked as thrombotic thrombocytopenia purpura? 61
24832123 2014
229
The role of mechanotransduction on vascular smooth muscle myocytes' [corrected] cytoskeleton and contractile function. 61
25125187 2014
230
An archaeologic dig: a rice-fruit diet reverses ECG changes in hypertension. 61
24996514 2014
231
Malignant hypertension and retinopathy in a western lowland gorilla (Gorilla gorilla gorilla). 61
24646309 2014
232
Potentially preventable hospitalization as a complication of CKD: a cohort study. 61
24731738 2014
233
Transcatheter therapies for resistant hypertension: Clinical review. 61
25228950 2014
234
Genetic similarities between tobacco use disorder and related comorbidities: an exploratory study. 61
25060307 2014
235
Author response on: Malignant hypertension and nephrotic range proteinuria without hematuria: IgA nephropathy. 61
25097347 2014
236
A rare consequence of malignant hypertension. 61
25029879 2014
237
Scleroderma renal crisis. 61
24833760 2014
238
Thrombotic microangiopathy resulting from neglected blood pressure control. 61
26877958 2014
239
Comment on: Malignant hypertension and nephrotic range proteinuria without hematuria: IgA nephropathy. 61
25120304 2014
240
Malignant hypertension and interferon-beta: a case report. 61
24067346 2014
241
[Occlusion of Peripheral Bypass - Changing of an Institutional Paradigm]. 61
27866403 2014
242
Atypical presentation of post infectious glomerulonephritis as malignant hypertension and thrombotic microangiopathy. 61
24701044 2014
243
Quiz page March 2014: A patient with malignant hypertension, thrombotic microangiopathy, and nephrotic-range proteinuria. 61
24560161 2014
244
hypertensive intracranial bleed due to mid aortic syndrome. 61
24068622 2014
245
Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention. 61
24368192 2014
246
Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. 61
24373528 2014
247
Consistency of racial variation in medical outcomes among publicly and privately insured living kidney donors. 61
24192712 2014
248
Adaptive optics assisted visualization of thickened retinal arterial wall in a patient with controlled malignant hypertension. 61
25336903 2014
249
Diagnosis of malignant hypertension with ocular examination: a child case. 61
24168178 2014
250
[Ocular involvement in malignant hypertension]. 61
25184026 2014
251
Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. 61
24210589 2014
252
Reappraisal of the etiology of extracorpuscular non-autoimmune acquired hemolytic anemia in 2657 hospitalized patients with non-neoplastic disease. 61
24808725 2014
253
[Treatment of hypertensive emergencies and malignant hypertension: the possibility of using urapidil]. 61
25902662 2014
254
Analysis of pathological data of renal biopsy at one single center in China from 1987 to 2012. 61
24791880 2014
255
Peduncular hallucinosis: a case report. 61
25249815 2014
256
Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud's phenomenon, positive antinuclear antibodies and hypertensive emergency. 61
24583433 2014
257
Clinical and renal biopsy findings predicting outcome in renal thrombotic microangiopathy: a large cohort study from a single institute in China. 61
25184151 2014
258
An uncommon cause of malignant hypertension. 61
23791591 2013
259
Renal nitric oxide synthase and antioxidant preservation in Cyp1a1-Ren-2 transgenic rats with inducible malignant hypertension. 61
23764378 2013
260
Malignant hypertension and nephrotic range proteinuria without hematuria: IgA nephropathy. 61
24049285 2013
261
[Bilateral stellate neuroretinitis as presenting sign of pheochromocytoma]. 61
23790444 2013
262
Frequency of serious outcomes in patients with hypertension as a chief complaint in the emergency department. 61
24005086 2013
263
Posterior reversible encephalopathy syndrome-an under recognized manifestation of Chronic Kidney Disease. 61
24339647 2013
264
Malignant hypertension: a preventable emergency. 61
24126748 2013
265
Malignant hypertension with protracted but not definitive oligoanuric acute kidney failure. 61
27293574 2013
266
Pregnancy, cesarean, and pheochromocytoma: a case report and literature review. 61
23527821 2013
267
Intussusception presenting with malignant hypertension and lethargy. 61
23914204 2013
268
A case of foreign accent syndrome. 61
23499353 2013
269
Hypertensive emergency: A unique manifestation of a pituitary disorder. 61
23961500 2013
270
A comprehensive assessment of cardiac structure and function in patients with treated malignant phase hypertension: the West Birmingham Malignant Hypertension project. 61
22192285 2013
271
An Extra-adrenal Pheochromocytoma Presenting as Malignant Hypertension-A Report of two cases. 61
23905134 2013
272
Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. 61
23788505 2013
273
Does obesity influence target organ damage and outcomes in patients with malignant phase hypertension? The West Birmingham Malignant Hypertension Project. 61
23407241 2013
274
[The origins of the Czech Society of Cardiology and of Czech cardiology]. 61
23808734 2013
275
A case of secondary focal segmental glomerulosclerosis associated with malignant hypertension. 61
28509227 2013
276
Central versus peripheral blood pressure in malignant hypertension; effects of antihypertensive treatment. 61
23467212 2013
277
Mesangial cells are responsible for orchestrating the renal podocytes injury in the context of malignant hypertension. 61
23445449 2013
278
Renal sympathetic denervation in resistant hypertension. 61
23675555 2013
279
Clinical characteristics and strategy for treatment of functional carotid body tumours. 61
23428895 2013
280
Impact of a novel mutation in the 5'-flanking region of natriuretic peptide precursor B gene on the antihypertensive effects of sodium nitroprusside in patients with hypertension. 61
22695938 2013
281
Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. 61
23458595 2013
282
Telmisartan prevents excess-salt-induced exacerbated (malignant) hypertension in spontaneously hypertensive rats. 61
22927675 2013
283
When the chimney is blocked: malignant renovascular hypertension after endovascular repair of abdominal aortic aneurysm. 61
23531087 2013
284
Graves' disease allied with multiple pheochromocytoma. 61
23776912 2013
285
Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma. 61
23248149 2013
286
Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension. 61
21708810 2013
287
A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension. 61
23448537 2013
288
22-Year-old patient with malignant hypertension associated with primary aldosteronism. 61
22739770 2013
289
Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy. 61
23377400 2013
290
Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. 61
23307303 2013
291
Intravitreal bevacizumab in persistent retinopathy secondary to malignant hypertension. 61
23964183 2013
292
Malignant hypertension with papilledema. 61
21820265 2013
293
Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e. 61
24348079 2013
294
Chronic perfusion of angiotensin II causes cognitive dysfunctions and anxiety in mice. 61
23103834 2013
295
Pre-nephrectomy angiotensin II type 1 receptor antibodies in living kidney donors: A concern? 61
25095528 2013
296
The spectrum of renal thrombotic microangiopathy in lupus nephritis. 61
23320601 2013
297
Prevalence in the General Population of a CFH Sequence Variant Associated with Atypical Haemolytic Uraemic Syndrome in an Extensive Family from Southwest England. 61
24163689 2013
298
Strongyloides stercoralis infection in transplanted patients. 61
23826469 2013
299
Reversible confluent deep white matter abnormalities: a new variant of posterior reversible encephalopathy syndrome. 61
24368950 2013
300
Renal artery embolization for managing uncontrolled hypertension in a kidney transplant candidate. 61
23984264 2013
301
Fulminant Idiopathic Intracranial Hypertension With Malignant Systemic Hypertension-A Case Report. 61
28163767 2013
302
Ectopic thoracic kidney and end-stage renal disease in a 38-year-old nigerian. 61
24527243 2013
303
Uremia and thrombotic microangiopathy: conditions that may havethe same manifestation. 61
23362978 2013
304
Malignant hypertension with reversible brainstem hypertensive encephalopathy and thrombotic microangiopathy. 61
22418002 2012
305
[Renal denervation: current state and future perspectives]. 61
23073661 2012
306
Malignant hypertension with an unusual presentation mimicking the immune mediated pulmonary renal syndrome. 61
23074127 2012
307
Current status of renal denervation in resistant hypertension. 61
23117009 2012
308
[Hypertensive emergency with clinical signs of a thrombotic microangiopathy]. 61
23168979 2012
309
Hemolytic-uremic syndrome, malignant hypertension and IgA nephropathy: successful treatment with plasma exchange therapy. 61
22892290 2012
310
Ultrasound assessment of optic disc edema in patients with headache. 61
22030203 2012
311
Usefulness of Intravenous Anesthesia Using a Target-controlled Infusion System with Local Anesthesia in Submuscular Breast Augmentation Surgery. 61
23094252 2012
312
Expression of NADPH oxidase and production of reactive oxygen species in aorta in an active immunization mouse model with AT1-EC2 peptide. 61
22886959 2012
313
Oximetry of retinal capillaries by multicomponent analysis. 61
22800727 2012
314
Thrombotic microangiopathy and associated renal disorders. 61
22802583 2012
315
Long-term renal outcome in patients with malignant hypertension: a retrospective cohort study. 61
22846257 2012
316
Vascular ventricular coupling in patients with malignant phase hypertension: the West Birmingham malignant hypertension project. 61
22357519 2012
317
Perinephric haematoma causing refractory hypertension in a 17-year-old male. 61
23197967 2012
318
Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. 61
22691955 2012
319
Neonatal midaortic syndrome and renal artery atresia presenting as malignant hypertension. 61
22447383 2012
320
[Pheochromocytoma: rare lethal challenging diagnosis that may be encountered by gynecologists and obstetricians]. 61
22227233 2012
321
Increased neuronal activity in the OVLT of Cyp1a1-Ren2 transgenic rats with inducible Ang II-dependent malignant hypertension. 61
22579820 2012
322
Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension: the West Birmingham Malignant Hypertension study. 61
22495136 2012
323
Mid-aortic syndrome in two preterm infants. 61
22538378 2012
324
Posterior reversible encephalopathy syndrome: a case study. 61
22546734 2012
325
[Clinical and pathological analyses of bevacizumab-induced renal impairment in four patients]. 61
22776601 2012
326
Subintimal renal artery angioplasty in a case of renal artery stenosis leading to malignant hypertension. 61
22479681 2012
327
Enrichment of (pro)renin receptor promoter with activating histone codes in the kidneys of spontaneously hypertensive rats. 61
21803797 2012
328
Hypertensive retinopathy in a child caused by pheochromocytoma: identification after a failed school vision screening. 61
22245022 2012
329
Malignant hypertension due to a large reninoma: a case report. 61
22574557 2012
330
Systemic sclerosis with thrombotic thrombocytopenia purpura and malignant hypertension. 61
22871138 2012
331
Bilateral nephrectomy as a rescue therapy for hemodialyzed patient with malignant hypertension - case report. 61
23197949 2012
332
Bilateral insular lesions related to malignant hypertension. 61
22790153 2012
333
A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. 61
22052055 2012
334
[Reversible posterior leukoencephalopathy syndrome (RPLS) associated with Wegener's granulomatosis: a case report and review of the literature]. 61
22975855 2012
335
Liver transplantation results in complete neurologic recovery from malignant hypertension secondary to fulminant hepatic failure: a case report. 61
22466917 2012
336
Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. 61
21975872 2012
337
Renal functional responses to selective intrarenal renin inhibition in Cyp1a1-Ren2 transgenic rats with ANG II-dependent malignant hypertension. 61
21993885 2012
338
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. 61
22130488 2012
339
The development of focal segmental glomerulosclerosis secondary to anabolic steroid abuse. 61
22669525 2011
340
Malignant hypertension secondary to renovascular disease during infancy--an unusual cause of failure to thrive. 61
21965587 2011
341
Recurrent malignant juxtaglomerular cell tumor: A rare cause of malignant hypertension in a child. 61
22121315 2011
342
Membranous nephropathy with crescents. 61
21903992 2011
343
Mineralocorticoid hypertension. 61
22145132 2011
344
Receptor-activating autoantibodies and disease: preeclampsia and beyond. 61
21895478 2011
345
[Significance of 3-methoxytyramine urine measurement in the diagnosis of pheochromocytomas and paragangliomas: about 28 patients]. 61
22008135 2011
346
Magnesium and vascular dysfunction in malignant hypertension. 61
21670414 2011
347
Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. 61
21720266 2011
348
[Renal involvement in patients with systemic sclerosis]. 61
21524952 2011
349
Correlation between HLA-DRB1, HLA-DQB1 polymorphism and autoantibodies against angiotensin AT(1) receptors in Chinese patients with essential hypertension. 61
21557256 2011
350
Hypercapnic cerebral edema presenting in a woman with asthma: a case report. 61
21599887 2011
351
Dutch guideline for the management of hypertensive crisis -- 2010 revision. 61
21646675 2011
352
Intravitreal bevacizumab in a patient with a macular star in malignant hypertension. 61
20954147 2011
353
Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension. 61
21358304 2011
354
A case of catatonia due to posterior reversible encephalopathy syndrome treated successfully with antihypertensives and adjunctive olanzapine. 61
21601735 2011
355
Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. 61
20012923 2011
356
Impact of malignant arterial hypertension on the heart. 61
21178780 2011
357
Increased risk of avoidable hospitalization among patients with schizophrenia. 61
21443824 2011
358
Persistent macrovascular and microvascular dysfunction in patients with malignant hypertension. 61
21263115 2011
359
The scleroderma kidney: progress in risk factors, therapy, and prevention. 61
21061100 2011
360
Enhancement of renin and prorenin receptor in collecting duct of Cyp1a1-Ren2 rats may contribute to development and progression of malignant hypertension. 61
21068087 2011
361
The optometrist's role in the management of hypertensive crises. 61
21168370 2011
362
[Hypertensive emergencies at the University Hospital Center in Brazzaville, Congo]. 61
21585107 2011
363
Clinical features of malignant hypertension with thrombotic microangiopathy. 61
21214403 2011
364
Bilateral central retinal vein occlusion caused by malignant hypertension in a young patient. 61
21166599 2011
365
Congestive heart failure as an initial manifestation of reninoma. 61
22308872 2011
366
IgA nephropathy associated with a novel N-terminal mutation in factor H. 61
20734203 2011
367
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. 61
21789188 2011
368
Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. 61
21629798 2011
369
Licorice consumption as a cause of posterior reversible encephalopathy syndrome: a case report. 61
21332974 2011
370
[Level of nitrous oxide in peripheral blood serum in patients with various severity of arterial hypertension]. 61
22304312 2011
371
Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. 61
21078594 2011
372
Malignant hypertension: a rare problem or is it underdiagnosed? 61
20626341 2010
373
Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. 61
20724906 2010
374
A 3-year old girl with seizures, hypokalemia and metabolic alkalosis. 61
22797482 2010
375
Long-term renal survival in malignant hypertension. 61
20299339 2010
376
Posterior reversible encephalopathy syndrome during posterior fossa tumor resection in a child. 61
20887113 2010
377
A case of systemic lupus erythematosus presenting as malignant hypertension with hypertensive retinopathy. 61
20830234 2010
378
Malignant hypertension associated with IgA nephropathy. 61
20840215 2010
379
Hemi-central retinal artery occlusion in young adults. 61
20689202 2010
380
[Unusual presentation of Wegener's granulomatosis]. 61
20605284 2010
381
Acute renal failure secondary to malignant hypertension induced thrombotic microangiopathy. 61
20635021 2010
382
Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in CYP1A1-REN2 transgenic rats. 61
20375689 2010
383
Thrombotic microangiopathy: new insights. 61
20186056 2010
384
A young boy with malignant hypertension and intracranial bleed. 61
20835329 2010
385
Prone retroperitoneoscopy in treating complex renal vascular malformations. 61
19664958 2010
386
AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high-salt diet. 61
20224314 2010
387
Value of retinal examination in hypertensive encephalopathy. 61
19865107 2010
388
Localized Serous Retinal Detachment of Macula as a Marker of Malignant Hypertension. 61
20337299 2010
389
Pheochromocytoma and Von Hippel-Lindau in pregnancy. 61
19784914 2010
390
Severe renal failure and microangiopathic hemolysis induced by malignant hypertension--case series and review of literature. 61
20129022 2010
391
Hypertensive optic neuropathy and choroidopathy in an 18-year-old woman with renal failure. 61
25390399 2010
392
[Scleroderma renal crisis]. 61
21875014 2010
393
Expression of eNOS in kidneys from hypertensive patients. 61
21694923 2010
394
Relationship between Calcium-Phosphorus Product and Severity of Valvular Heart Insufficiency in Patients Undergoing Chronic Hemodialysis. 61
23074572 2010
395
[Haemospermia in malignant hypertension]. 61
20393631 2010
396
Milk Products Containing Bioactive Tripeptides Have an Antihypertensive Effect in Double Transgenic Rats (dTGR) Harbouring Human Renin and Human Angiotensinogen Genes. 61
20721338 2010
397
Common genetic variants in the chromogranin a promoter are associated with renal injury in IgA nephropathy patients with malignant hypertension. 61
20113265 2010
398
Hypertensive retinopathy grade iv in an 11-year-old girl with renal arterial hypertension due to recurrent reflux pyelonephritis. 61
25390672 2010
399
The current state of endovascular therapy in the evaluation and management of renovascular disease. 61
21326543 2009
400
Improving survival of malignant hypertension patients over 40 years. 61
19696746 2009
401
Emergency department headache admissions in an acute care hospital:why do they occur and what can we do about it? 61
19956825 2009
402
[Acute renal failure associated with malignant hypertension]. 61
19847731 2009
403
An unusual non-immunological cause of renal pulmonary syndrome. 61